Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS

Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug...

Full description

Saved in:
Bibliographic Details
Published in:American journal of Alzheimer's disease and other dementias 2020-01, Vol.35, p.1533317519899546
Main Authors: Akimoto, Hayato, Negishi, Akio, Oshima, Shinji, Wakiyama, Haruna, Okita, Mitsuyoshi, Horii, Norimitsu, Inoue, Naoko, Ohshima, Shigeru, Kobayashi, Daisuke
Format: Article
Language:English
Subjects:
Aged
Alzheimer Disease - diagnosis
Current Topics in Research
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Exenatide - therapeutic use
Female
Glucagon-Like Peptides - analogs & derivatives
Glucagon-Like Peptides - therapeutic use
Humans
Hypoglycemic Agents - adverse effects
Immunoglobulin Fc Fragments - therapeutic use
Liraglutide - therapeutic use
Male
Metformin - adverse effects
Metformin - therapeutic use
Recombinant Fusion Proteins - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P < .001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P < .001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P = .014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P = .011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.
ISSN:1533-3175
1938-2731
DOI:10.1177/1533317519899546